Atara Biotherapeutics, Inc.

243 articles with Atara Biotherapeutics, Inc.

• Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - March 03, 2023

  3/3/2023

  Atara Biotherapeutics, Inc., a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, reported the grant of 62,350 restricted stock units of Atara’s common stock to six newly hired employees.

• Atara Biotherapeutics to Participate in Cell Therapy Panel Discussion at the Cowen 43rd Annual Health Care Conference

  3/1/2023

  Atara Biotherapeutics, Inc. (Nasdaq: ATRA) today announced that Pascal Touchon, President and Chief Executive Officer, will participate in a cell therapy panel discussion at the Cowen 43rd Annual Health Care Conference on Wednesday, March 8, 2023 at 11:10 a.m. PST / 2:10 p.m. EST.

• Atara Biotherapeutics to Participate in the H.C. Wainwright Cell Therapy Virtual Conference

  2/21/2023

  Atara Biotherapeutics, Inc. (Nasdaq: ATRA) today announced that Pascal Touchon, President and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright Cell Therapy Virtual Conference on Tuesday, February 28, 2023 at 12:00 p.m. PST / 3:00 p.m. EST.

• Pierre Fabre to Commercialize and Distribute the First Approved Allogeneic T-cell Immunotherapy in Europe Following Transfer of the European Commission Marketing Authorization of EBVALLO™ (tabelecleucel)

  2/8/2023

  Pierre Fabre and Atara Biotherapeutics, Inc. (Nasdaq: ATRA) today announced the transfer of the European Commission (EC) marketing authorization (MA) for EBVALLO™ (tabelecleucel) for patients with relapsed or refractory Epstein‑Barr virus positive post‑transplant lymphoproliferative disease (EBV+ PTLD) from Atara to Pierre Fabre.

• Atara Biotherapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Operational Progress

  2/8/2023

  Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the fourth quarter and full year 2022, recent business highlights and key upcoming catalysts for 2023.

• Atara Biotherapeutics to Announce Fourth Quarter and Full Year 2022 Financial Results on Wednesday, February 8, 2023

  2/6/2023

  Atara Biotherapeutics, Inc. today announced the Company will release fourth quarter and full year 2022 financial results after market close on Wednesday, February 8, 2023.

• Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - February 03, 2023

  2/3/2023

  Atara Biotherapeutics, Inc. reported the grant of 36,750 restricted stock units of Atara’s common stock to three newly hired employees and stock options to purchase an aggregate of 48,300 shares of Atara’s common stock to two such newly hired employees.

• Atara Biotherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Jan 13, 2023

  1/13/2023

  Atara Biotherapeutics, Inc. reported the grant of 66,800 restricted stock units of Atara’s common stock to six newly hired employees and stock options to purchase an aggregate of 40,000 shares of Atara’s common stock to one such newly hired employee.

• Atara Biotherapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

  1/4/2023

  Atara Biotherapeutics, Inc. (Nasdaq: ATRA) today announced that Pascal Touchon, President and Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023 at 3:45 PM PST / 6:45 PM EST at the Westin St. Francis Hotel in San Francisco.

• Atara Biotherapeutics Announces $31 Million Royalty Interest Financing Agreement with HealthCare Royalty

  12/20/2022

  Atara Biotherapeutics, Inc. (Nasdaq: ATRA) has entered into a royalty interest financing agreement totaling $31 million with HealthCare Royalty (HCRx) for Ebvallo™ in Europe and other territories covered by Atara’s commercialization agreement with Pierre Fabre.

• Atara Biotherapeutics’ Ebvallo™ (tabelecleucel) Receives European Commission Approval as First Ever Therapy for Adults and Children with EBV+ PTLD

  12/19/2022

  Atara Biotherapeutics’ Ebvallo ™ (tabelecleucel) Receives European Commission Approval as First Ever Therapy for Adults and Children with EBV+ PTLD.

• Atara Biotherapeutics Announces Changes to Its Board of Directors

  12/19/2022

  Atara Biotherapeutics, Inc. (Nasdaq: ATRA) today announced that Carol Gallagher will assume the role of Chair of the Board of Directors, replacing Ron Renaud, who is stepping down to focus on his new position as Managing Director at Bain Capital Life Sciences.

• Atara Biotherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - December 15, 2022

  12/15/2022

  Atara Biotherapeutics, Inc., a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, reported the grant of inducement awards to Ricardo Fonseca, its new Vice President, Operations.

• Atara Biotherapeutics Presents Updated Clinical Data from Pivotal Phase 3 Trial (ALLELE) of Tab-cel® at the 64th American Society of Hematology (ASH) Annual Meeting

  12/12/2022

  Atara Biotherapeutics, Inc. (Nasdaq: ATRA) today announced updated interim analysis and safety results from its Phase 3 multicenter ALLELE study investigating tabelecleucel (tab-cel®) for the treatment of relapsed/refractory (r/r) Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD) following solid organ transplant (SOT) or hematopoietic cell transplant (HCT).

• Atara Biotherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - December 02, 2022

  12/2/2022

  Atara Biotherapeutics, Inc. reported the grant of 33,150 restricted stock units of Atara’s common stock to five newly hired employees and stock options to purchase an aggregate of 13,375 shares of Atara’s common stock to one such newly hired employee.

• Atara Biotherapeutics to Participate at the Evercore ISI 5th Annual HealthCONx Conference

  11/23/2022

  Atara Biotherapeutics, Inc. today announced that Pascal Touchon, President and Chief Executive Officer, will participate in a virtual fireside chat at the Evercore ISI 5th Annual HealthCONx Conference on Wednesday, November 30, 2022, at 2:15 p.m.

• Atara Biotherapeutics to Participate at the 2022 Stifel Healthcare Conference

  11/9/2022

  Atara Biotherapeutics, Inc. announced that AJ Joshi, MD, Chief Medical Officer, and Utpal Koppikar, Chief Financial Officer, will participate in a fireside chat at the Stifel Healthcare Conference in New York on Wednesday, November 16, 2022, at 1:50 p.m. EST.

• Atara Biotherapeutics Announces Third Quarter 2022 Financial Results and Operational Progress

  11/8/2022

  Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the third quarter 2022, recent business highlights, and key upcoming catalysts.

• Atara Biotherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - November 04, 2022

  11/4/2022

  Atara Biotherapeutics, Inc., a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, reported the grant of 7,200 restricted stock units of Atara’s common stock to two newly hired employees.

• Atara Biotherapeutics to Announce Third Quarter 2022 Financial Results on Tuesday, November 8, 2022

  11/1/2022

  Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the Company will release third quarter 2022 financial results after market close on Tuesday, November 8, 2022.